Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
CHICAGO–( BUSINESS WIRE )– Exicure, Inc. (Nasdaq: XCUR, pull out (NASDAQ: ), the company has entered into a memorandum of understanding (MOU) with GPCR Therapeutics, Inc. to acquire GPCR USA, a subsidiary of GPCR Therapeutics. (GPCR Therapeutics) on December 24, 2024. and technology transfer and collaborative research in GPCR therapeutics’ ongoing drug development pipeline. Through this acquisition, Execure plans to acquire all of the shares of GPCR USA held by GPCR Therapeutics and retain key technical personnel. Following this, Execure intends to receive a technology transfer with the FDA for GPCR Therapeutics’ CXCR4 inhibitor, which is currently in Phase 2 clinical trials, along with related patents and intellectual property (IP). With excellent research expertise and clinical pipeline, Exicure aims to advance as a clinical-stage biotech company. GPCR Therapeutics plans to successfully complete ongoing clinical trials involving stem cell mobilizing agents (SCM) targeting multiple myeloma patients and prepare for clinical studies related to acute myeloid leukemia (AML). The market size for advanced Phase 2 trials is estimated to be around $1 billion to $2 billion per year.
In addition, Exure plans to engage in collaborative research and development in various forms. GPCR Therapeutics, Exicure’s partner in this MOU, is a South Korean drug development company focused on GPCRs (G protein-coupled receptors, GPCRs), which represent one-third of all drug targets. GPCR Therapeutics has secured patents targeting popular GPCRs such as CXCR4 and has several pipelines targeting leukemia and solid tumors, genetic disorders, idiopathic pulmonary fibrosis and obesity. Dr. Pina Cardarelli, who previously served as a vice president at Bristol-Myers Squibb (NYSE: ) , first led immuno-oncology drugs such as Yarvoy (ipilimumab) and Opdivo (nivolumab). Chief Scientific Officer (CSO) of GPCR Therapeutics since 2019.
In the year In 2021, GPCR Therapeutics established a subsidiary in the US to align R&D with global pharmaceutical standards and needs. At the American Society of Hematology (SHA) conference held December 7-10, 2024, GPCR Therapeutics presented three exhibits detailing: (1) interim results of ongoing Phase 2 trials, (2) information on improving treatment efficacy for acute myeloid leukemia (AML). and (3) preclinical data to enhance T cell responses, including in vivo CAR-T It offers a variety of treatments. Additionally, on December 24, 2024, Exicure completed an $8.7 million capital investment. Combined with the $2 million capital investment on December 9, 2024, the $1.3 million raised in November and an additional $4 million expected, the company plans to raise a total of $14 million in capital investments. The funds will be used primarily for GPCR USA, clinical trial costs and the acquisition of its ongoing operations.
About GPCR Therapeutics, Inc.
GPCR Therapeutics, Inc., headquartered in Seoul, South Korea, is a clinical-stage global biopharmaceutical company with an innovative approach to developing therapeutics built on proprietary GPCR data. The company’s lead small molecule property, GPC-100/Burixafor, targets CXCR4, one of the chemokine GPCRs overexpressed in various cancers. GPCR Therapeutics is currently conducting a Phase 2 clinical trial in the US to evaluate the efficacy of the combination of GPC-100 and propranolol in patients with multiple myeloma. The company is actively working with local and international biotechnology companies. By targeting the unique pharmacology of GPCR couples, GPCR Therapeutics aims to develop life-changing treatments for cancer and other diseases. In particular, the interaction between CXCR4 and the beta-2 adrenergic receptor (B2AR) provides an alternative signaling pathway that depends on CXCR4 and B2AR activation.
About Exicure, Inc.
Exicure, Inc. An early-stage biotechnology company focused on developing ribonucleic acid therapeutics targeting proven targets. Following its recent restructuring and divestment of clinical and development activities, the Company is seeking strategic options to maximize shareholder value from its historical biotechnology assets and, more broadly, to maximize shareholder value. For more information, visit www.exicicuretx.com.
Forward-looking statements
This press release They include forward-looking statements within the meaning of the safe harbor provisions of the United States Securities Litigation Reform Act of 1995. There can be no assurance regarding the ability to comply with the Panel’s decision and the applicable detailed criteria by the deadline. or later. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied in this report. Such risks include, among others, the possibility that we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company will not adequately comply with the panel’s decision, and the risk that Nasdaq may ultimately fail. Cancellation of Company’s Common Stock. All of these factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to revise or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on forward-looking statements that speak only as of the date of this report.
Check out the source version on businesswire.com: https://www.businesswire.com/news/home/20241226044292/am/
Josh Miller
847-673-1700
media@exicicuretx.com
Source: Exicure, Inc.
